Tumor response, CD3 + CD8+, CD3 + CD4+, CD3+, CD3-CD56+, tumor marker (SCC-Ag, CYFRA21–1, CEA), miR-155, miR-24, adverse reaction, 1-year/2-year/3-year survival rate. This evidence concerns the gene CD4 and neoplasm.